The company aims to become a personalized digital coach for any diseases that require weight control.

LOS ANGELES, CA, December 07, 2023 /24-7PressRelease/ — Bionutrion (CEO, Ju Young Kim), which was selected in the category of health & wellbeing for the ‘2023 Non-face-to-face leading service activation project in the life-based field’ by the National IT Industry Promotion Agency (NIPA), is a company that uses artificial intelligence-based personalized nutrition prescription and coaching program (BIO-NUTRI) to help users turn on their bodies’ metabolic switch to be healthy. Today, Bionutrion is a growing company that creates digital therapeutic devices for the assessment and management of non-alcoholic fatty liver disease.

The company is conducting a demonstration project with the support of the NIPA for a task to apply non-face-to-face personalized nutrition prescription and digital coaching program for health management of patients with non-alcoholic fatty liver disease. In the future, the company aims to become a personalized digital coach for any diseases that require weight control.

Non-alcoholic fatty liver disease may lead to liver cirrhosis and liver cancer rarely, and is associated with a four to eight times higher risk of diabetes and cardiovascular disease. However, there is no cure and hospital-based systematic management is not yet in place, according to an official’s explanation. Bionutrion’s Dr. Coach is the combination of a year of scientific research outcome and an evidence-based weight loss program, presented in an app and dietary replacement.

Divided into two phases, initial weight loss and weight maintenance, the program provides a well-organized diet for medical treatment effort and cognitive behavioral therapy based on Acceptance-Commitment Therapy (ACT) and Dialectical Behavior Therapy (DBT) to help users reset their mindset for the difficult journey of weight control. It also incorporates AI-based dietary management and coaching programs to increase efficiency and scalability.

“Non-alcoholic fatty liver disease is actually a part of the systemic disease, not just a liver problem, and is difficult to control without an integrated, systematic, and patient-centered treatment program. Recent weight-control medications are recognized for having potential in treating non-alcoholic fatty liver disease in terms of its effect, but in the stage where the complexity of mechanisms worsens the disease, inhibiting just one of them is not the end of the treatment,” an official from Bionutrion explained.

“Continuous management and change of mindset must take precedence due to the nature of obesity. I believe that mastering management through disease control is the safeguard against yo-yo syndrom and relapse. The role of helping people adjust their lifestyles while simultaneously targeting the prevention and treatment of obesity is essential, and this is an area where Bionutrion hopes to make a significant contribution,” the official emphasized.

For the original version of this press release, please visit here